|Bid||0.6850 x N/A|
|Ask||0.7500 x N/A|
|Day's range||0.6700 - 0.7150|
|52-week range||0.4100 - 1.3500|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
EBR Systems, Inc. (ASX: EBR), the medical device company developing wireless cardiac pacing systems, has met its primary safety and efficacy endpoints in its pivotal SOLVE-CRT trial of the WiSE® Cardiac Resynchronization Therapy (CRT) System.
EBR Systems, Inc. (ASX: "EBR", "EBR Systems", or the "Company"), developer of the world's only wireless cardiac pacing system for heart failure, is pleased to announce that the Company's WiSE® technology will be featured at the 15th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Singapore from the 18th to the 20th of November.